BG
LEGN icon

Bellevue Group’s Legend Biotech LEGN Stock Holding History

Bellevue Group’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$955K Sell
33,054
-2,832
-8% -$76.4K 0.02% 102
2026
Q1 		$649K Sell
35,886
-28,085
-44% -$535K 0.02% 103
2025
Q4 		$1.39M Sell
63,971
-21,005
-25% -$602K 0.03% 107
2025
Q3 		$2.77M Sell
84,976
-462
-0.5% -$17.1K 0.06% 90
2025
Q2 		$3.03M Sell
85,438
-5,753
-6% -$186K 0.07% 89
2025
Q1 		$3.09M Sell
91,191
-76,150
-46% -$2.73M 0.07% 95
2024
Q4 		$5.45M Sell
167,341
-1,793
-1% -$74.3K 0.1% 94
2024
Q3 		$8.24M Sell
169,134
-200,136
-54% -$10.7M 0.13% 91
2024
Q2 		$16.4M Buy
369,270
+76,000
+26% +$3.51M 0.27% 84
2024
Q1 		$16.4M Buy
293,270
+91,516
+45% +$5.52M 0.25% 83
2023
Q4 		$12.1M Sell
201,754
-76,400
-27% -$4.84M 0.19% 84
2023
Q3 		$18.7M Buy
278,154
+2,400
+0.9% +$167K 0.3% 75
2023
Q2 		$19M Sell
275,754
-231,500
-46% -$15.1M 0.27% 81
2023
Q1 		$24.5M Buy
507,254
+152,465
+43% +$7.46M 0.35% 71
2022
Q4 		$17.7M Sell
354,789
-270,672
-43% -$13.1M 0.24% 89
2022
Q3 		$25.5M Sell
625,461
-4,978
-0.8% -$234K 0.37% 72
2022
Q2 		$34.7M Sell
630,439
-29,630
-4% -$1.25M 0.49% 59
2022
Q1 		$24M Buy
660,069
+2,413
+0.4% +$95.3K 0.28% 89
2021
Q4 		$30.7M Buy
657,656
+371,100
+130% +$18.8M 0.32% 86
2021
Q3 		$14.5M Sell
286,556
-103,607
-27% -$4.31M 0.15% 105
2021
Q2 		$16M Sell
390,163
-213,080
-35% -$7.24M 0.16% 113
2021
Q1 		$17.5M Buy
603,243
+186,902
+45% +$5.1M 0.19% 103
2020
Q4 		$11.7M Buy
+416,341
New +$12M 0.13% 113
2020
Q3 		– Sell
-134,261
Closed -$5.71M – 219
2020
Q2 		$5.71M Buy
+134,261
New +$5.25M 0.08% 122

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Bellevue Group's LEGN Position: Q2 2026 in Review

Bellevue Group reduced its Legend Biotech (LEGN) stake by 7.9% in Q2 2026, selling an estimated $76.4K and leaving 33,054 shares worth $955K. The position accounts for 0.02% of the portfolio, ranked #102.

Bellevue Group first reported a position in LEGN in Q2 2020 and has held it in 24 quarters since. The position peaked at $34.7M in Q2 2022. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Bellevue Group held 33,054 shares of Legend Biotech worth $955K as of Q2 2026.
  • Bellevue Group sold 2,832 Legend Biotech shares in Q2 2026, an estimated $76.4K.
  • Legend Biotech made up 0.02% of Bellevue Group's portfolio in Q2 2026, its #102 holding.
  • Bellevue Group first reported a position in Legend Biotech in Q2 2020 and has held it in 24 quarters since.
  • Bellevue Group's Legend Biotech position peaked at $34.7M in Q2 2022.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.